Australia markets closed

AbCellera Biologics Inc. (ABCL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.34+0.03 (+0.41%)
At close: 04:00PM EDT
7.55 +0.21 (+2.86%)
Pre-market: 08:30AM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
485,424
485,424
375,203
233,155
11,612
Cost of revenue
66,436
66,436
45,516
27,143
-
Gross profit
418,988
418,988
329,687
206,012
-
Operating expenses
Research development
107,879
107,879
62,062
29,393
10,113
Selling general and administrative
66,755
66,755
48,761
15,752
4,012
Total operating expenses
191,923
191,923
107,788
41,661
13,954
Operating income or loss
227,065
227,065
221,899
164,351
-2,343
Interest expense
4,045
4,045
5,225
6,511
209.196
Total other income/expenses net
-
-
-855
-300
186.056
Income before tax
239,099
239,099
219,149
157,833
-2,211
Income tax expense
80,580
80,580
65,685
38,915
-
Income from continuing operations
158,519
158,519
153,464
118,918
-2,211
Net income
158,519
158,519
153,464
118,918
-2,211
Net income available to common shareholders
158,519
158,519
153,464
85,101
-2,211
Basic EPS
-
0.56
0.56
0.53
-0.01
Diluted EPS
-
0.50
0.48
0.45
-0.01
Basic average shares
-
285,057
275,764
159,195
172,380
Diluted average shares
-
314,827
318,294
263,130
172,380
EBITDA
-
276,246
241,624
169,615
-154.612